Lastly, in 2019, results from the multicenter single-arm Phase II NICHE trial were published by Dziadziuszko et al., testing afatinib, an EGFR inhibitor, in 13 NSCLC patients pre-treated with platinum-based CHT harboring HER2 mutations. Here, EGFR is linked to non-small cell lung carcinoma.